MW032

DRUG2 trials

Sponsors

Mabwell (Shanghai) Bioscience Co., Ltd.

Conditions

Bone MetastasesBone Tumor

Phase 1

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults

CompletedNCT04798326

Mabwell (Shanghai) Bioscience Co., Ltd.Bone Tumor

Start: 2019-06-25End: 2020-02-26Updated: 2021-03-15

Phase 3

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

CompletedNCT04812509

Mabwell (Shanghai) Bioscience Co., Ltd.Bone Metastases

Start: 2020-03-20End: 2022-01-28Updated: 2023-02-24

Related Papers

Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases

JAMA Oncology2024-02-086 citations

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial

BioDrugs2023-02-2111 citations